Intravenous busulfan for autologous stem cell transplantation in adult patients with acute myeloid leukemia: A survey of 952 patients on behalf of the acute leukemia working party of the european group for blood and marrow transplantation

Arnon Nagler, Myriam Labopin, Norbert Claude Gorin, Felicetto Ferrara, Miguel A. Sanz, Depei Wu, Antonio Torres Gomez, Simona Lapusan, Giuseppe Irrera, Jose E. Guimaraes, Aida Botelho Sousa, Angelo M. Carella, Norbert Vey, William Arcese, Avichai Shimoni, Raanan Berger, Vanderson Rocha, Mohamad Mohty

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Oral busulfan is the historical backbone of the busulfan+cyclophosphamide regimen for autologous stem cell transplantation. However intravenous busulfan has more predictable pharmacokinetics and less toxicity than oral busulfan; we, therefore, retrospectively analyzed data from 952 patients with acute myeloid leukemia who received intravenous busulfan for autologous stem cell transplantation. Most patients were male (n=531, 56%), and the median age at transplantation was 50.5 years. Two-year overall survival, leukemia-free survival, and relapse incidence were 67±2%, 53±2%, and 40±2%, respectively. The non-relapse mortality rate at 2 years was 7±1%. Five patients died from veno-occlusive disease. Overall leukemia-free survival and relapse incidence at 2 years did not differ significantly between the 815 patients transplanted in first complete remission (52±2% and 40±2%, respectively) and the 137 patients transplanted in second complete remission (58±5% and 35±5%, respectively). Cytogenetic risk classification and age were significant prognostic factors: the 2-year leukemia-free survival was 63±4% in patients with good risk cytogenetics, 52±3% in those with intermediate risk cytogenetics, and 37 ± 10% in those with poor risk cytogenetics (P=0.01); patients ≤50 years old had better overall survival (77±2% versus 56±3%; P

Original languageEnglish
Pages (from-to)1380-1386
Number of pages7
JournalHaematologica
Volume99
Issue number8
DOIs
Publication statusPublished - Aug 1 2014

Fingerprint

Busulfan
Stem Cell Transplantation
Blood Group Antigens
Acute Myeloid Leukemia
Leukemia
Transplantation
Bone Marrow
Cytogenetics
Survival
Recurrence
Incidence
Surveys and Questionnaires
Cyclophosphamide
Pharmacokinetics
Mortality

ASJC Scopus subject areas

  • Hematology
  • Medicine(all)

Cite this

Intravenous busulfan for autologous stem cell transplantation in adult patients with acute myeloid leukemia : A survey of 952 patients on behalf of the acute leukemia working party of the european group for blood and marrow transplantation. / Nagler, Arnon; Labopin, Myriam; Gorin, Norbert Claude; Ferrara, Felicetto; Sanz, Miguel A.; Wu, Depei; Gomez, Antonio Torres; Lapusan, Simona; Irrera, Giuseppe; Guimaraes, Jose E.; Sousa, Aida Botelho; Carella, Angelo M.; Vey, Norbert; Arcese, William; Shimoni, Avichai; Berger, Raanan; Rocha, Vanderson; Mohty, Mohamad.

In: Haematologica, Vol. 99, No. 8, 01.08.2014, p. 1380-1386.

Research output: Contribution to journalArticle

Nagler, A, Labopin, M, Gorin, NC, Ferrara, F, Sanz, MA, Wu, D, Gomez, AT, Lapusan, S, Irrera, G, Guimaraes, JE, Sousa, AB, Carella, AM, Vey, N, Arcese, W, Shimoni, A, Berger, R, Rocha, V & Mohty, M 2014, 'Intravenous busulfan for autologous stem cell transplantation in adult patients with acute myeloid leukemia: A survey of 952 patients on behalf of the acute leukemia working party of the european group for blood and marrow transplantation', Haematologica, vol. 99, no. 8, pp. 1380-1386. https://doi.org/10.3324/haematol.2014.105197
Nagler, Arnon ; Labopin, Myriam ; Gorin, Norbert Claude ; Ferrara, Felicetto ; Sanz, Miguel A. ; Wu, Depei ; Gomez, Antonio Torres ; Lapusan, Simona ; Irrera, Giuseppe ; Guimaraes, Jose E. ; Sousa, Aida Botelho ; Carella, Angelo M. ; Vey, Norbert ; Arcese, William ; Shimoni, Avichai ; Berger, Raanan ; Rocha, Vanderson ; Mohty, Mohamad. / Intravenous busulfan for autologous stem cell transplantation in adult patients with acute myeloid leukemia : A survey of 952 patients on behalf of the acute leukemia working party of the european group for blood and marrow transplantation. In: Haematologica. 2014 ; Vol. 99, No. 8. pp. 1380-1386.
@article{e914e7fd0f53494cb89c8964ccebb7ce,
title = "Intravenous busulfan for autologous stem cell transplantation in adult patients with acute myeloid leukemia: A survey of 952 patients on behalf of the acute leukemia working party of the european group for blood and marrow transplantation",
abstract = "Oral busulfan is the historical backbone of the busulfan+cyclophosphamide regimen for autologous stem cell transplantation. However intravenous busulfan has more predictable pharmacokinetics and less toxicity than oral busulfan; we, therefore, retrospectively analyzed data from 952 patients with acute myeloid leukemia who received intravenous busulfan for autologous stem cell transplantation. Most patients were male (n=531, 56{\%}), and the median age at transplantation was 50.5 years. Two-year overall survival, leukemia-free survival, and relapse incidence were 67±2{\%}, 53±2{\%}, and 40±2{\%}, respectively. The non-relapse mortality rate at 2 years was 7±1{\%}. Five patients died from veno-occlusive disease. Overall leukemia-free survival and relapse incidence at 2 years did not differ significantly between the 815 patients transplanted in first complete remission (52±2{\%} and 40±2{\%}, respectively) and the 137 patients transplanted in second complete remission (58±5{\%} and 35±5{\%}, respectively). Cytogenetic risk classification and age were significant prognostic factors: the 2-year leukemia-free survival was 63±4{\%} in patients with good risk cytogenetics, 52±3{\%} in those with intermediate risk cytogenetics, and 37 ± 10{\%} in those with poor risk cytogenetics (P=0.01); patients ≤50 years old had better overall survival (77±2{\%} versus 56±3{\%}; P",
author = "Arnon Nagler and Myriam Labopin and Gorin, {Norbert Claude} and Felicetto Ferrara and Sanz, {Miguel A.} and Depei Wu and Gomez, {Antonio Torres} and Simona Lapusan and Giuseppe Irrera and Guimaraes, {Jose E.} and Sousa, {Aida Botelho} and Carella, {Angelo M.} and Norbert Vey and William Arcese and Avichai Shimoni and Raanan Berger and Vanderson Rocha and Mohamad Mohty",
year = "2014",
month = "8",
day = "1",
doi = "10.3324/haematol.2014.105197",
language = "English",
volume = "99",
pages = "1380--1386",
journal = "Haematologica",
issn = "0390-6078",
publisher = "NLM (Medline)",
number = "8",

}

TY - JOUR

T1 - Intravenous busulfan for autologous stem cell transplantation in adult patients with acute myeloid leukemia

T2 - A survey of 952 patients on behalf of the acute leukemia working party of the european group for blood and marrow transplantation

AU - Nagler, Arnon

AU - Labopin, Myriam

AU - Gorin, Norbert Claude

AU - Ferrara, Felicetto

AU - Sanz, Miguel A.

AU - Wu, Depei

AU - Gomez, Antonio Torres

AU - Lapusan, Simona

AU - Irrera, Giuseppe

AU - Guimaraes, Jose E.

AU - Sousa, Aida Botelho

AU - Carella, Angelo M.

AU - Vey, Norbert

AU - Arcese, William

AU - Shimoni, Avichai

AU - Berger, Raanan

AU - Rocha, Vanderson

AU - Mohty, Mohamad

PY - 2014/8/1

Y1 - 2014/8/1

N2 - Oral busulfan is the historical backbone of the busulfan+cyclophosphamide regimen for autologous stem cell transplantation. However intravenous busulfan has more predictable pharmacokinetics and less toxicity than oral busulfan; we, therefore, retrospectively analyzed data from 952 patients with acute myeloid leukemia who received intravenous busulfan for autologous stem cell transplantation. Most patients were male (n=531, 56%), and the median age at transplantation was 50.5 years. Two-year overall survival, leukemia-free survival, and relapse incidence were 67±2%, 53±2%, and 40±2%, respectively. The non-relapse mortality rate at 2 years was 7±1%. Five patients died from veno-occlusive disease. Overall leukemia-free survival and relapse incidence at 2 years did not differ significantly between the 815 patients transplanted in first complete remission (52±2% and 40±2%, respectively) and the 137 patients transplanted in second complete remission (58±5% and 35±5%, respectively). Cytogenetic risk classification and age were significant prognostic factors: the 2-year leukemia-free survival was 63±4% in patients with good risk cytogenetics, 52±3% in those with intermediate risk cytogenetics, and 37 ± 10% in those with poor risk cytogenetics (P=0.01); patients ≤50 years old had better overall survival (77±2% versus 56±3%; P

AB - Oral busulfan is the historical backbone of the busulfan+cyclophosphamide regimen for autologous stem cell transplantation. However intravenous busulfan has more predictable pharmacokinetics and less toxicity than oral busulfan; we, therefore, retrospectively analyzed data from 952 patients with acute myeloid leukemia who received intravenous busulfan for autologous stem cell transplantation. Most patients were male (n=531, 56%), and the median age at transplantation was 50.5 years. Two-year overall survival, leukemia-free survival, and relapse incidence were 67±2%, 53±2%, and 40±2%, respectively. The non-relapse mortality rate at 2 years was 7±1%. Five patients died from veno-occlusive disease. Overall leukemia-free survival and relapse incidence at 2 years did not differ significantly between the 815 patients transplanted in first complete remission (52±2% and 40±2%, respectively) and the 137 patients transplanted in second complete remission (58±5% and 35±5%, respectively). Cytogenetic risk classification and age were significant prognostic factors: the 2-year leukemia-free survival was 63±4% in patients with good risk cytogenetics, 52±3% in those with intermediate risk cytogenetics, and 37 ± 10% in those with poor risk cytogenetics (P=0.01); patients ≤50 years old had better overall survival (77±2% versus 56±3%; P

UR - http://www.scopus.com/inward/record.url?scp=84905197533&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84905197533&partnerID=8YFLogxK

U2 - 10.3324/haematol.2014.105197

DO - 10.3324/haematol.2014.105197

M3 - Article

C2 - 24816236

AN - SCOPUS:84905197533

VL - 99

SP - 1380

EP - 1386

JO - Haematologica

JF - Haematologica

SN - 0390-6078

IS - 8

ER -